The future of HIV microbicides: Challenges and opportunities

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 4, 2009, Pages 143-150

  Garg, Anita B ^a   Nuttall, Jeremy ^a   Romano, Joseph ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; DAPIVIRINE; ENFUVIRTIDE; MARAVIROC; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; MIV 150; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PRO 2000; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIVAGEL; AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VAGINA FLORA; VIROTHERAPY; VIRUS TRANSMISSION; FEMALE; GROWTH, DEVELOPMENT AND AGING; INTRAVAGINAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; FEMALE; HIV; HIV INFECTIONS; HUMANS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 65549169986     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020901900401     Document Type: Review

References (74)

1. Steinbrook R. The AIDS epidemic - a progress report from Mexico City. N Engl J Med 2008; 359:885-887.
2. UNAIDS. 2008 Report on the global AIDS epidemic. (Updated 1 July 2008. Accessed 27 January 2009.) Available from http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp
3. Dionisio D, Gass R, McDermott P, et al. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world? Curr HIV Res 2007; 5:155-187. (Pubitemid 46488194)
4. Gaym A. Microbicides-emerging essential pillars of comprehensive HIV/AIDS prevention. Ethiop Med J 2006; 44:405-415.
5. Ramjee G, Doncel GF, Mehendale S, Tolley EE, Dickson K. Microbicides 2008 conference: from discovery to advocacy. AIDS Res Ther 2008; 5:19.
6. Honey K. HIV vaccine trial no longer PAVEs the way. J Clin Invest 2008; 118:2989.
7. Senior K. Back to basics for HIV vaccine research. Lancet Infect Dis 2008; 8:467.
8. Williams BG, Lloyd-Smith JO, Gouws E, et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med 2006; 3:e262.
9. Nuttall J, Romano J, Douville K, et al. The future of HIV prevention: prospects for an effective anti-HIV microbicide. Infect Dis Clin North Am 2007; 21:219-239. (Pubitemid 46745254)
10. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised, controlled trial. Lancet 2002; 360:971-977. (Pubitemid 35284107)
11. Beer BE, Doncel GF, Krebs FC, et al. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 2006; 50:713-723.
12. Scordi-Bello IA, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of antihuman immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49:3607-3615. (Pubitemid 41233007)
13. Skoler-Karpoff S, Ramgee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomized double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
14. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463-472.
15. Microbicides Trial Network. HPTN 035 Q&A. (Updated 13 January 2009. Accessed 27 January 2009.) Available from http://www.mtnstopshiv.org/node/349
16. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007; 2:561-566.
17. Williams DL, Newman DR, Ballagh SA, et al. Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm. Sex Transm Dis 2007; 34:977-984.
18. Van de Wijgert J, Jones H. Challenges in microbicide trial design and implementation. Stud Fam Plann 2006; 37:123-129. (Pubitemid 43905635)
19. Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol 2003; 26:121-132.
20. Mori T, Boyd MR. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother 2001; 45:664-672. (Pubitemid 32182005)
21. Ketas TJ, Schader SM, Zurita J, et al. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 2007; 364:431-440. (Pubitemid 46873705)
22. International Partnership for Microbicides. Advancing HIV-prevention options for women. Annual report 2006. (Accessed 27 January 2009.) Available at http://www.ipm-microbicides.org/pdfs/english/ipm-publications/2007/ IPM%20Annual%20Report-2006-FINAL-eng.pdf
23. Philpott SM. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003; 1:217-227.
24. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30:1228-1250.
25. Gaertner H, Offord R, Botti P, Kuenzi G, Hartley O. Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein. Bioconjug Chem 2008; 19:480-489. (Pubitemid 351294920)
26. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99-102. (Pubitemid 41599827)
27. Fung HB, Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 2004; 26:352-378 (Pubitemid 38457330)
28. Kitchen CM, Nuño M, Kitchen SG, Krogstad P. Enfuvirtide antiretroviral therapy in HIV-1 infection. Ther Clin Risk Manag 2008; 4:433-439. (Pubitemid 351714701)
29. Veazey RS, Ketas TA, Klasse PJ, et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci U S A 2008; 105:10531-10536.
30. Fox M. Group gets to test new Merck AIDS drug in gel. (Updated 11 March 2008. Accessed 5 February 2009.) Available from http://www.reuters.com/article/ ousiv/idUSN1051563720080311
31. Knipe DM, Howley PM, Griffin DE, et al. HIVs and their replication. In Fields Virology. 5th edn. Edited by DM Knipe & PM Howley. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins 2006; pp. 2127-2129.
32. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 2008; 300:555-570.
33. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543-551. (Pubitemid 43731598)
34. HIV Prevention Trials Network. HPTN 059: Phase II expanded safety and acceptability study of the vaginal microbicide 19. Tenofovir gel. (Updated: 1 July 2007. Accessed 27 January 2009). Available from http://www.hptu.org/ research-studies/hptn059.asp
35. Rodriquez E. Viread gets FDA nod. Posit Living 2001; 10:33.
36. Portsmouth SD, Scott CJ. The renaissance of fixed dose combinations: Combivir. Ther Clin Risk Manag 2007; 3:579-583.
37. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
38. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14.
39. Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res 2006; 71:343-350. (Pubitemid 44223773)
40. Romano J, Malcolm RK, Garg S, Rohan LC, Kaptur PE. Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS 2008; 3:558-566.
41. L'homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine, pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22:557-565.
42. Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56:954-956.
43. Raymond EG, Chen PL, Condon S, et al. Acceptability of five nonoxynol-9 spermicides. Contraception 2005; 71:438-442.
44. Lete I, Doval JL, Perez-Campos E, et al. Factors affecting women's selection of a combined hormonal contraceptive method: The TEAM-06 Spanish cross-sectional study. Contraception 2007; 76:77-83. (Pubitemid 47090168)
45. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008; 111:267-277. (Pubitemid 351653415)
46. Roth S, Monsour M, Dowland A, et al. Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells. Antimicrob Agents Chemother 2007; 51:1972-1978. (Pubitemid 46903082)
47. Mauck CK, Creinin MD, Barnhart KT, et al. A phase I comparative postcoital testing study of three concentrations of C31G. Contraception 2004; 70:227-231.
48. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3:e1474. (Pubitemid 351796318)
49. HIV Prevential Trials Network. HPTN Studies. (Updated 7 June 2007. Accessed 27 January 2009.) Available from http://www.hptn.org/research-studies. asp
50. Schwartz JL, Kovalevsky G, Lai JJ, et al. A randomized sixday safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex Transm Dis 2008; 35:414-419. (Pubitemid 351440786)
51. Jespers VA, Van Roey JM, Beets GI, Buvé AM. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 2007; 44:154-158.
52. Smythe S, Ferreira MM, Kapiga S, et al. Clinical safety and tolerability assessment of an anti-HIV dapivirine vaginal microbicide gel (Gel-002). Microbicides 2008 Conference. 24-27 February 2008, New Delhi, India. Abstract B09-546.
53. Nel A, Coplan P, Smythe S, Douville K, Romano J, Mitchnick M. Pharmacokinetic assessment of an anti-HIV dapivirine vaginal microbicide gel (Gel-002). Microbicides 2008 Conference. 24-27 February 2008, New Delhi, India. Abstract B020-563.
54. Nel A, Smythe S, Young K, Malcolm K, Rosenberg Z, Romano J. Safety and pharmacokinetic assessment of 28 day anti-HIV dapivirine intravaginal microbicide rings. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 559b.
55. Joshi SN, Dutta S, Kumar BK, et al. Expanded safety study of Praneem polyherbal vaginal tablet among HIV un-infected women in Pune, India: a phase II clinical trial report. Sex Transm Infect 2008; 84: 343-347.
56. Al-Jamal WT, Kostarelos K. Construction of nonoscale multicompartment liposomes for combinatory drug delivery. Int J Pharm 2007; 331:182-185.
57. Wang C, Ye W, Zheng Y, Liu X, Tong Z. Fabrication of drug-loaded biodegradable microcapsules for controlled release by combination of solvent evaporation and layer-bylayer self-assembly. Int J Pharm 2007; 338:165-173. (Pubitemid 46777230)
58. Kim Y-M, Lim J-O, Kim H-K, Kim S-Y, Shin J-P. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide. Eur J Pharm Biopharm 2008; 70:179-186.
59. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003; 17:1597-1604. (Pubitemid 36951680)
60. Denton PW, Estes JD, Sun Z, et al. Antiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16. (Pubitemid 351198263)
61. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306:485-487. (Pubitemid 39372448)
62. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:5577-5586. (Pubitemid 30346592)
63. Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006; 193:27-35.
64. Min SS, Corbett AH, Rezk N, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004; 37:1577-1580. (Pubitemid 39658196)
65. Launay O, Tod M, Louchahi K, et al. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother 2004; 48:632-634. (Pubitemid 38141731)
66. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46:719-725. (Pubitemid 351321556)
67. 14C] dapivirine for 7 days. Antimicrob Agents Chemother 2008; 52:909-914.
68. Mauck CK, Katz D, Sandefer EP, et al. Vaginal distribution of Replens and K-Y Jelly using three imaging techniques. Contraception 2008; 77:195-204.
69. Barnhart KT, Pretorius ES, Shaunik A, Timbers K, Nasution M, Mauck C. Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 mL). Contraception 2005; 72:65-70. (Pubitemid 40827121)
70. Henderson MH, Couchman GM, Walmer DK, et al. Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception 2007; 75:142-151.
71. Braun KE, Boyer JD, Henderson MH, Katz DF, Wax A. Label-free measurement of microbicidal gel thickness using low coherence interferometry. J Biomed Opt 2006; 11:020504. (Pubitemid 44355066)
72. Grant RM, Hamer D, Hope T, et al. Whither or wither microbicides? Science 2008; 321:532-534.
73. Hafez ESE. The comparative anatomy of the mammalian cervix. In The Biology of the Cervix. Edited by RJ Blandau & K Moghissi. Chicago: University of Chicago Press 1973; pp. 23-56.
74. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 2000; 96:431-439.